Follow us:
PRESS RELEASE : Ypso-Facto is part of the CALIPSO project led by Sanofi, to disrupt the production of biomedicines!
Supported by Bpifrance, the CALIPSO project aims at developing a new generation of tools that will disrupt industrial bioproduction processes.
Nancy, France, 16 Sept 2021 - Ypso-Facto is proud to play a major role in this challenging and exciting project. With its expertise in bioprocesses and predictive simulation , Ypso-Facto will develop software solutions to support production of innovative therapies. The company will work on...
CALIPSO: revolutionizing the management of bioproduction processes in healthcare
Paris (France) – September 16th, 2021 – Sanofi, Capgemini, Ypso-Facto, GPC Bio, CEA, CentralSupelec announce the launch of the project CALIPSO !
A structuring R&D project for French medical research, financed and coordinated by a consortium of high-profile industrial and public actors. An essential mobilisation to accelerate access to new treatments at an acceptable cost, to ensure France’s competitiveness and its health independence...
Ypso-Facto invests 1.4M€ in the development of a collaborative software suite for process design and evaluation
The company has received 800k€ from European Regional Development Fund (ERDF) to support the development of Ypso-Proxima®
Nancy, France, January 14th, 2021 - Ypso-Facto, a company specialized in the development and optimization of processes for the Life Sciences Industries invests 1.4M€, including € 800,000 from the European Regional Development Fund (ERDF), to support the development of its software suite Ypso-Proxima®...
NEW ARTICLE - Comparison of mAb single-use DSP processes by Sanofi using Ypso-Proxima
EASY: a disruptive mAb purification process to reduce cost of goods
This article [1] illustrates how Ypso-Proxima allows a rational comparison between two biopharmaceutical DSP processes. The innovative EASY mAb purification process developed by Sanofi is matched against the standard proteinA-based DSP counterpart. Relying on Proxima's process evaluation, the...
NEW ARTICLE – Fareva and Ypso-Facto investigate the purification of an antibiotic by ion-exchange
Using Mechanistic Modeling for Understanding Antibiotics Purification with Ion Exchange Chromatography
This article is based on a real industrial purification process by Fareva and highlights the power of mechanistic modeling for process development: Our client needed to change a raw material to secure his supply chain. From a process point of view, it was supposed to be seamless. However, a...Indépendance sanitaire : La tribune de Roger-Marc Nicoud
“ Retrouver l’indépendance pour la production d’API : une chance pour les CDMO européennes ? "
La crise actuelle rappelle à l’Europe (et sans doute à l’Amérique du Nord) les limites de la délocalisation de la production. C’est le cas pour de nombreux produits, incluant bon nombre d’ingrédients pharmaceutiques actifs (API) et de médicaments en général. Cela ouvre la possibilité...Feature article – Regaining independence in API production: A chance for European CDMOs
Roger-Marc Nicoud, CEO of Ypso-Facto, looks at the challenges and opportunities for CDMOs in the current crisis
The current crisis has highlighted the dependence of European and, indeed, North American countries on delocalised production. This is the case for many goods, including APIs and drugs in general. The opportunity is now there for European CDMOs to win additional business, but effort and adaptation...
COVID-19 STATEMENT
Nancy (France), 25th March 2020
In this unprecedented situation, our number one priority is the safety and well-being of our people and those around us. This is the reason why all our teams are working remotely. Please be assured that, while ensuring everyone’s health and safety, we remain focused on continued service to our...
Ypso-Facto is a service company helping industrial firms to develop, optimize and secure their chemical processes and bioprocesses.
Download
© Ypso-Facto 2014 - Powered by Ealys | Legal Information